GDC 4379
Alternative Names: GDC-4379; RG-6244Latest Information Update: 08 Feb 2022
At a glance
- Originator Genentech
- Class Antiasthmatics; Small molecules
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 05 Sep 2021 Safety and pharmacokinetics data from phase I trial in Asthma presented at 31st Annual Congress of the European Respiratory Society (ERS-2021)
- 28 Apr 2021 Discontinued - Phase-I for Asthma in New Zealand (Inhalation) (Roche pipeline, April 2021)
- 10 Jul 2020 Genentech reinitiates a phase I trial in Asthma in New Zealand (Inhalation) (ACTRN12619000227190)